The cyclin-dependent kinase inhibitor, p21 WAF1 , promotes angiogenesis by repressing gene transcription of thioredoxin-binding protein 2 in cancer cells
Open Access
- 21 September 2009
- journal article
- research article
- Published by Oxford University Press (OUP) in Carcinogenesis
- Vol. 30 (11) , 1865-1871
Abstract
The cyclin-dependent kinase inhibitor, p21 WAF1 , induces cell-cycle arrest and can act as a tumor suppressor. However, increasing evidence indicates that p21 WAF1 can also increase resistance to some anticancer therapies and thus promote tumor growth. The mechanisms explaining this paradox have not been explained. We found that conditioned media from MCF-7 breast cancer cells transfected with a p21 WAF1 -specific small interfering RNA (siRNA) significantly reduced endothelial cell migration, invasion and vascular sprouting. Liquid chromatography/mass spectrometry analysis of the conditioned media revealed that p21 WAF1 knockdown significantly reduced secretion of thioredoxin (Trx), a redox protein known to promote tumor angiogenesis. p21 WAF1 knockdown decreased Trx enzymatic activity in cancer cells, by effects on the expression levels of intracellular thioredoxin-binding protein 2 (TBP2), known to bind and inactivate Trx. Consistent with these findings, media from cancer cells transfected with TBP2 siRNA promoted endothelial cell invasion and blocked the anti-angiogenic effect of p21 WAF1 siRNA. Addition of Trx siRNA blocked the pro-angiogenic effects of TBP2 siRNA. Chromatin immunoprecipitation assays showed p21 WAF1 bound TBP2 gene promoter. Taken together, our data suggests that p21 WAF1 can induce Trx secretion and angiogenesis in cancer cells, by direct transcriptional repression of the TBP2 promoter.Keywords
This publication has 24 references indexed in Scilit:
- Activation of tissue transglutaminase transcription by histone deacetylase inhibition as a therapeutic approach for Myc oncogenesisProceedings of the National Academy of Sciences, 2007
- Extracellular thioredoxin and thioredoxin-binding protein 2 in control of cancerSeminars in Cancer Biology, 2006
- Is p21 an oncogene?Molecular Cancer Therapeutics, 2006
- Tumorigenic activity of p21Waf1/Cip1 in thymic lymphomaOncogene, 2006
- Induction of p21CIP/WAF-1 and G2 arrest by ionizing irradiation impedes caspase-3-mediated apoptosis in human carcinoma cellsOncogene, 2005
- A Phase I Clinical Trial of the Sequential Combination of Irinotecan Followed by FlavopiridolClinical Cancer Research, 2005
- The mTOR Inhibitor RAD001 Sensitizes Tumor Cells to DNA-Damaged Induced Apoptosis through Inhibition of p21 TranslationCell, 2005
- Cancer without diseaseNature, 2004
- Dynamic Expression Profile of p21WAF1/CIP1 and Ki-67 Predicts Survival in Rectal Carcinoma Treated With Preoperative RadiochemotherapyJournal of Clinical Oncology, 2003
- Tumorigenesis and the angiogenic switchNature Reviews Cancer, 2003